Shopping Cart
Remove All
Your shopping cart is currently empty
Enavatuzumab (Synonyms: PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361)
Catalog No. T76865 Copy Product Info
🥰Excellent
Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research.
Enavatuzumab
Copy Product Info🥰Excellent
Catalog No. T76865
Synonyms PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361
Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research.
Enavatuzumab
Cas No. 1062149-33-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $622 | In Stock | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research. |
| In vitro | Enavatuzumab has growth inhibiting activity in a wide range of cancer cell lines in vitro. Enavatuzumab (10 μg/mL) and cells incubated together for 24 hours resulted in significantly increased migration of immune effector cells to SN12C and A375 tumor cells. [1] |
| In vivo | Enavatuzumab achieved 70% tumor growth inhibition (TGI) in vivo against H358 tumors.[2] |
| Synonyms | PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF12A/TWEAKR/CD266 |
| Molecular Weight | 150 kDa |
| Cas No. | 1062149-33-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Enavatuzumab | purchase Enavatuzumab | Enavatuzumab cost | order Enavatuzumab | Enavatuzumab in vivo | Enavatuzumab in vitro | Enavatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.